Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity
Osimertinib exerts off-target immunomodulatory effects by activating the tumor-extrinsic NLRP3 inflammasome, linking mitochondrial-lysosomal crosstalk to antitumor immunity. NLRP3 and IL-1β in TAMs emerge as predictive biomarkers for EGFR-TKI efficacy, while rIL-1β combination therapy represents a novel strategy to enhance clinical outcomes.
Authors
- Yueyin Pan (ORCID: https://orcid.org/0000-0003-0532-5368)
- Haibo Wu (ORCID: https://orcid.org/0000-0002-5961-2947)
- Yan Li (ORCID: https://orcid.org/0000-0001-9079-8826)
- Xumei Liu (ORCID: https://orcid.org/0000-0001-9218-2822)
- Yubei Sun
- Haiyang Yu (ORCID: https://orcid.org/0000-0002-4085-9472)
- Jing Pan (ORCID: https://orcid.org/0000-0003-3185-1070)
- Xin Sun (ORCID: https://orcid.org/0009-0008-9611-0605)
- Xiao-Jun Qian
- Hongbin He
Institutions
- University of Science and Technology of China (CN)
- Anhui Medical University (CN)
- Chinese Academy of Sciences (CN)
- Hefei Institutes of Physical Science (CN)
- Center for Excellence in Molecular Cell Science (CN)
- Anhui Provincial Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Hefei First People's Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-012182
- Citations
- 3
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.42